



Incretin Base Therapy

GLP 1 Agonist

DPP4 Inhibitor

Dr. Farzad Najafipour

Endocrine Research Center, Tabriz University of Medical Sciences



ALHAVI
Pharmaceutical Co.
Since 1968


Introduction

Despite advances in options for the treatment of diabetes, optimal glycemic control is often **not achieved**.

Hypoglycemia and **weight gain** associated with many antidiabetic medications may interfere with the implementation and long term application of "intensive" therapies.


**Treatment of
Type 2
Diabetes**

Sulfonylureas (and insulin)




**Treatment of
Type 2
Diabetes**

Sulfonylureas (and insulin)




Metformin




**Treatment of
Type 2
Diabetes**

Sulfonylureas (and insulin)



Metformin




**Treatment of
Type 2
Diabetes**


Thiazolidinediones



Sulfonylureas (and insulin)




Metformin




**Treatment of
Type 2
Diabetes**

Thiazolidinediones




GLP-I analogs & DPP IV inhibitors

Sulfonylureas (and insulin)




Metformin




**Treatment of
Type 2
Diabetes**

Thiazolidinediones



GLP-I analogs & DPP IV inhibitors



SGLT2 inhibitors


Historical perspectives of incretins and evolution of incretin based therapy

Year	Development
1932	La Barre et al coined the term (Incretin) and defined its effect
1964	Incretin effect (Significant Insulin release on oral ingestion than Intravenous injection)
1966	DPP-4 enzyme first described
1970	GIP demonstrated
1985	GLP 1 demonstrated
1995	GIP & GLP 1 were demonstrated to be degraded by DPP-4 enzyme
2006	Sitagliptin introduced for the use of T2DM

Glucagon-like Peptide 1


GLP-1 is produced from the proglucagon gene in L cells of the small intestine and is secreted in response to nutrients.

L-cells secrete GLP-1




The Effect of Incretins in Type 2 Diabetes and Non-Diabetes

Healthy controls




Type 2 diabetes




The Effect of Incretins in Type 2 Diabetes and Non-Diabetes

Healthy controls



Type 2 diabetes




Oral glucose load



Intravenous (IV) glucose infusion

The Effect of Incretins in Type 2 Diabetes and Non-Diabetes

Healthy controls




Oral glucose load




Intravenous (IV) glucose infusion

Type 2 diabetes



The Effect of Incretins in Type 2 Diabetes and Non-Diabetes

Healthy controls




Oral glucose load



Intravenous (IV) glucose infusion

Type 2 diabetes



همه موارد زیر صحیح است به جزء؟

تجویز خوراکی گلوکز باعث افزایش بیشتر انسولین و C-Peptide در مقابل تجویز وریدی گلوکز میشود

اثر Incretin باعث افزایش GLP-1 است.

داروهای مهارکننده DPP4 باعث افزایش اثر GLP-1 می شود.

آگونیست GLP-1 باعث کاهش ترشح انسولین می شود.

DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes


Ingestion
of food




DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes

Ingestion
of food


GI tract




DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes




DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes




DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes




DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes




DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes



DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes



DPP-4 Inhibitors Improve Glucose Control by Increasing Incretin Levels in Type 2 Diabetes



همه موارد زیر در مورد آگونیست **GLP-1** صحیح است به جزء؟

(a) باعث بهبود عملکرد سلولهای بتای پانکراس می شود.

(b) باعث کاهش فشار خون می شود.

(c) باعث کاهش اشتها می شود

(d) باعث افزایش **Hepatic glucose output** می شود.

GLP-1 Receptor agonists

GLP-1 exhibits a short half-life of one to two minutes due to N-terminal degradation by the enzyme DPP-4.

Synthetic GLP-1 receptor agonists are variably **resistant** to degradation by the enzyme **DPP-4** and therefore have a longer half-life, facilitating clinical use.

Exenatide, Liraglutide, Albiglutide, Taspoglutide, Lixisenatide, Dulaglutide, **oral and subcutaneous** Semaglutide

Type 2 Diabetes Treatment Efficacy

Change in
 HbA_{1c} (%)

Change in
body weight (kg)

Type 2 Diabetes Treatment Efficacy

	Change in HbA _{1c} (%)	Change in body weight (kg)
SUs	High	Gain

Type 2 Diabetes Treatment Efficacy

	Change in HbA _{1c} (%)	Change in body weight (kg)
SUs	High	Gain
TZDs	High	Gain

Type 2 Diabetes Treatment Efficacy

	Change in HbA _{1c} (%)	Change in body weight (kg)
SUs	High	Gain
TZDs	High	Gain
GLP-1RAs	High	Loss

Type 2 Diabetes Treatment Efficacy

	Change in HbA _{1c} (%)	Change in body weight (kg)
SUs	High	Gain
TZDs	High	Gain
GLP-1RAs	High	Loss
DPP-4Is	Intermediate	Neutral

Type 2 Diabetes Treatment Efficacy

	Change in HbA _{1c} (%)	Change in body weight (kg)
SUs	High	Gain
TZDs	High	Gain
GLP-1RAs	High	Loss
DPP-4Is	Intermediate	Neutral
Insulin	Highest	Gain

Type 2 Diabetes Treatment Efficacy

	Change in HbA _{1c} (%)	Change in body weight (kg)
SUs	High	Gain
TZDs	High	Gain
GLP-1RAs	High	Loss
DPP-4Is	Intermediate	Neutral
Insulin	Highest	Gain



Type 2 Diabetes Treatment Efficacy

	Change in HbA _{1c} (%)	Change in body weight (kg)
SUs	High	Gain
TZDs	High	Gain
GLP-1RAs	High	Loss
DPP-4Is	Intermediate	Neutral
Insulin	Highest	Gain



Weight loss **is common** with GLP-1 receptor agonists

کدام دسته دارویی زیر بیشترین کاهش وزن را ایجاد می کند؟

آگونیست GLP-1

مهارکننده DPP4

مهارکننده SGLT2

سولفونیل اوره

GLP-1 receptor agonists and **DPP4 inhibitors** are **not considered as initial therapy** for the majority of patients with type 2 diabetes.

Initial therapy in most patients with type 2 diabetes should begin with diet, weight reduction, exercise, and metformin.

Basal Insulin Plus GLP-1 RA

When used in combination with basal insulin, patients using GLP-1 receptor agonists compared with placebo achieved glycemic targets at **reduced insulin doses** and less hypoglycemia or weight gain.

DPP4 Inhibitors


Will the DPP-4 inhibitors replace GLP-1 mimetics?

DPP-4 inhibitors have similar action to GLP-1 agonists but **do not result in weight loss**; therefore, for patients in whom weight loss is needed, GLP-1 agonists are indicated.


Lack of weight loss with DPP-4 inhibition is thought to be due to lesser increase in GLP-1 levels (3x) compared with that of GLP-1 mimetic (10x).

DPP 4 Inhibitors


DPP 4 Inhibitors



DPP 4 Inhibitors




DPP 4 Inhibitors




DPP 4 Inhibitors

FDA 1st safety communication about
saxagliptin and heart failure




DPP 4 Inhibitors


FDA 1st safety communication about
saxagliptin and heart failure




DPP 4 Inhibitors



DPP 4 Inhibitors



DPP 4 Inhibitors






FDA added warnings about the risk of hospitalization for heart failure to the labels of **Saxagliptin** and **Alogliptin** containing type 2 diabetes medicines.

Clinicians may consider prescribing GLP-1 receptor agonists, SGLT-2 inhibitors, or DPP-4 inhibitors more routinely after metformin rather than sulfonylureas or basal insulin.

Sitagliptin: Once-daily Dosing Administration

The recommended dose of Sitagliptin is 100 mg once daily as monotherapy or as combination therapy with metformin or others drugs.


Sitagliptin Consistently and Significantly Lowers A1C With Once-Daily Dosing in Monotherapy



*Between group difference in LS means.

1. Diabetes Care. 2006;29(12):2632-7. 2- Diabetes Res Clin Pract. 2008 ;79(2):291-8 . 3. Diabetologia. 2006 ;49(11):2564-71.

A1C, FPG, and 2-hour PPG placebo-adjusted results in a 24-week study of sitagliptin



Although DPP-4 inhibitors are not considered as initial therapy for the majority of patients with type 2 diabetes, they can be used as monotherapy or add on therapy in patients with type 2 diabetes who are **intolerant of**, have **contraindications** to, or who are **inadequately controlled** on metformin or other glucose-lowering agents.

In particular, linagliptin might be a good choice as initial therapy in a patient with chronic kidney disease at risk for hypoglycemia.

Linagliptin Efficacy

Linagliptin achieves HbA1c decrease of up to 1.2% in poorly controlled patients.

Linagliptin is the only DPP-4 inhibitor which is primarily excreted by gut.

Linagliptin is the first only DPP-4 inhibitor that does not require dose adjustment.

Linagliptin Has Broad Therapeutic Indication

Independent of:



Linagliptin Has Broad Therapeutic Indication

Independent of:

Age




Linagliptin

5^{mg}
once
daily


Linagliptin Has Broad Therapeutic Indication

Independent of:




Linagliptin Has Broad Therapeutic Indication

Independent of:




Linagliptin Has Broad Therapeutic Indication

Independent of:




Linagliptin Has Broad Therapeutic Indication

Independent of:




Linagliptin Has Broad Therapeutic Indication

Independent of:



Linagliptin Has Broad Therapeutic Indication

Independent of:



Linagliptin

No dose adjustment is necessary in patients with renal or hepatic impairment.

Linagliptin-metformin is available in a single tablet

Empagliflozin-linagliptin is available as a combination pill (10 mg/5 mg and 25 mg/5 mg).

There are inadequate data to support the use of DPP-4 inhibitors in combination with **prandial insulin**.

Combination therapy with GLP-1 receptor agonists and DPP-4 inhibitors does not provide additive glucose lowering effects, and thus, the combination should be avoided.

Can DPP-4 inhibitors be used in comorbid conditions ?

Elderly

Renal

Hepatic impairment

Elderly

Age is not a comorbid disease condition per se but usually a constellation that increases the likelihood of comorbid diseases.

In elderly patients with T2DM, reductions in Hb A1c after treatment with a DPP-4 inhibitor were not significantly different from those in younger patients and the use of DPP-4 inhibitors was associated with a **low risk of hypoglycemia** and also **weight neutrality**.

Renal impairment

With reduced GFR, toxicity of the oral drugs increases as the drugs tend to accumulate in the body. Except linagliptin every gliptin dose has to be reduced in case of moderate to severe renal impairment.

Hepatic impairment

No significant changes in liver enzymes were reported with DPP-4 inhibitors alone or in combination with various other glucose-lowering agents.

همه جملات زیر درباره مهارکننده DPP4 صحیح است به جزء؟

در افراد مسن با تجویز مهارکننده DPP4 ریسک هیپوگلیسمی افزایش نمی یابد.

تجویز مهارکننده DPP4 بر روی کاهش وزن تاثیری زیادی ندارد.

تجویز مهارکننده DPP4 در بیماران با افزایش آنزیم های کبدی کنتراینده است.

داروی مهارکننده DPP4 در هر زمانی از طول روز قابل تجویز است و به زمان غذا خوردن

بستگی ندارد.

Because they do not cause hypoglycaemia, they do not require dose titration and can be taken at **any time of day**, independently of meal times.

They are also generally **free of drug–drug interactions** and can mostly be used with other medications without the need for dose adjustment of either agent.

Cardiovascular effects

DPP-4 inhibitors have generally **neither reduced nor increased** cardiovascular events (or the development or progression of kidney disease).

Sitagliptin Cardiovascular Outcomes Study (TECOS)

Main inclusion criteria

1. Patients aged ≥ 50 years with T2D
2. HbA_{1c} 6.5–8.0% receiving stable oral glucose-lowering therapy and/or insulin*
3. Pre-existing vascular disease

+ Usual care for T2D

Sitagliptin 100 mg daily

vs

Placebo

N = 14,671; median follow-up 3.0 years


Primary endpoint: time to first occurrence of:

- CV-related death
- Unstable angina requiring hospitalisation
- Non-fatal stroke
- Non-fatal MI

Conclusion:

Among patients with type 2 diabetes and established cardiovascular disease, adding **sitagliptin** to usual care **did not** appear to **increase** the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events.

Association of second-line antidiabetic medications with cardiovascular events among insured adults with type 2 diabetes



Side effects:

The incidence of side effects and hypoglycemia are **very low**.

In clinical trials, the most common reported side effects of DPP4 inhibitors include **nasopharyngitis**, **upper respiratory tract infection**, **urinary tract infection** and **headache**.

Adverse Effects

Musculoskeletal

Some DPP-4 inhibitors (sitagliptin, vildagliptin, saxagliptin) have been associated with **severe joint pain**. Other reported musculoskeletal side effects include myalgias, muscle weakness, and muscle spasms.

Symptoms have been reported from two days to five months after initiating DPP-4 inhibitors.

Adverse Effects

Skin

In postmarketing reports, sitagliptin, saxagliptin, linagliptin, and alogliptin have been associated with **hypersensitivity reactions**, including anaphylaxis, angioedema, and blistering skin conditions, including Stevens-Johnson syndrome.

DPP-4 inhibitors are contraindicated in patients with a history of a serious hypersensitivity reaction after previous exposure.

Adverse Effects

Pancreas

Acute pancreatitis has been reported in association with DPP-4 inhibitors. At the current time, there are insufficient data to know if there is a causal relationship.

If pancreatitis is confirmed, a DPP-4 inhibitor should not be restarted.

In addition, DPP-4 inhibitors should not be initiated in a patient with a history of pancreatitis.

**Incretin based drugs and risk of cholangiocarcinoma among
patients with type 2 diabetes:
population based cohort study.**

Compared with use of other second or third line antidiabetic drugs, use of DPP-4 inhibitors, and possibly GLP-1 receptor agonists, might be associated with an increased risk of **cholangiocarcinoma** in adults with type 2 diabetes.

Association of Diabetes Mellitus and Cholangiocarcinoma: Update of Evidence and the Effects of Antidiabetic Medication

The association between incretin-based therapy and the risk of CCA needs further clarification, as metformin is being studied in an ongoing clinical trial.

Mortality

DPP-4 inhibitors do not appear to have any effect on overall mortality.

بیمار آقای ۵۲ ساله با دیابت تیپ ۲ مراجعه کرده است. وی سالهاست که تحت درمان با انسولین می باشد و با آزمایشات زیر مراجعه کرده است:

FBS=150 mg/dl HbA1C=8.5% Cr=2.9 mg/dl Tg=155 mg/dl

Total cholesterol=180 mg/dl HDL-C=39 mg/dl

تجویز کدام دارو در بیمار ارجحتر است؟

Linagliptin

متفورمین

Sitagliptin

Zip-Met

خانم ۴۵ ساله ای با دیابت نوع ۲ که تحت درمان با متفورمین روزانه ۲۰۰۰ mg می باشد با آزمایشات زیر مراجعه کرده است.

FBS=185 mg/dl

BS 2hpp= 230 mg/dl

HbA1C= 8.2%

BMI=40 kg/m²

WT=120 kg

کدام درمان داروی در بیمار ارجحتر است؟

اضافه کردن سولفونیل اوره

اضافه کردن انسولین Lantus

اضافه کردن پیوگلیتازون

اضافه کردن آگونیست GLP-1



Thank you